Diabetic Neuropathy News and Research

RSS
Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.
Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

Innovative nerve graft transplant successful in treatment and prevention of posterior pressure ulcers

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

TENS therapy is not effective against chronic low-back pain

TENS therapy is not effective against chronic low-back pain

Second successful phrenic nerve decompression surgery

Second successful phrenic nerve decompression surgery

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Data from Phase 1 safety study of SB-728-T announced

Data from Phase 1 safety study of SB-728-T announced

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

The Quigley Corporation announces financial results for the third quarter of 2009

The Quigley Corporation announces financial results for the third quarter of 2009

University of Michigan to develop novel therapy for neuropathic pain

University of Michigan to develop novel therapy for neuropathic pain

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

New cutting edge nerve procedure relieves migraine permanently

New cutting edge nerve procedure relieves migraine permanently

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Sangamo declares pricing of common stock; grants option to purchase additional 450,000 shares

Sangamo declares pricing of common stock; grants option to purchase additional 450,000 shares

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Doris Duke Innovations award for sickle cell disease research

Doris Duke Innovations award for sickle cell disease research

New drug combination releives neuropathic pain and improves sleep

New drug combination releives neuropathic pain and improves sleep

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic